Has Bibi Das received payments from drug or device companies?

Yes. Drug and device makers reported $1,370,438 in general payments to Bibi Das across 2,419 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Bibi Das did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Bibi Das come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Bibi Das

Psychiatry · Stanford, CANPI 1528012374

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $893,269 of the $1,370,438 with a category attached, or 65.2%. 17 manufacturers reported payments, led by Axsome Therapeutics, Inc. at 31.1% of the total. 2025 is the largest year on record at $392,407, 2.4 times the $161,014 reported in 2019. Among psychiatry clinicians in CA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$1,370,438in general payments, 2019–2025

Across 2,419 payments — averaging $566.53 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Axsome Therapeutics, Inc.$427K
AbbVie$297K
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$273K
Neurocrine Biosciences, Inc.$92K
Sunovion Pharmaceuticals Inc.$90K
Otsuka America Pharmaceutical, Inc.$80K
plus $113K from 11 others

What the payments were for

Consulting fees$226,69217%
Speaking & faculty fees$893,26965%
Travel & lodging$207,73915%
Food & beverage$42,4633%
Education$2760%

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Axsome Therapeutics, Inc.	573	$426,872
AbbVie(2 entities)	762	$296,899
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)	345	$272,845
Neurocrine Biosciences, Inc.	123	$92,008
Sunovion Pharmaceuticals Inc.	189	$89,649
Otsuka America Pharmaceutical, Inc.	160	$79,563
Teva Pharmaceuticals USA, Inc.	111	$54,256
Vanda Pharmaceuticals Inc.	40	$32,523
E.r. Squibb & Sons, L.L.C.	39	$23,289
Takeda Pharmaceuticals U.S.A., Inc.	34	$1,408
Lundbeck LLC	31	$710
Otsuka Pharmaceutical Development & Commercialization, Inc.	2	$142
Corium, LLC	1	$77
Alkermes, Inc.	3	$72
Eisai Inc.	2	$55
Shire North American Group Inc	3	$45
Indivior Inc.	1	$27

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

Auvelity$413,722
VRAYLAR$283,821
CAPLYTA$267,880
INGREZZA$89,375
LATUDA$86,766
REXULTI$77,431
AUSTEDO$34,790
Fanapt$31,913
COBENFY$19,820
UZEDY$17,942
TRINTELLIX$600
VIIBRYD$200

How this compares

$1,370,438 in reported general payments places this provider in the 95th percentile of 4,954 psychiatry providers in California.

See all psychiatry providers in California →

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
TrintellixVortioxetine Hydrobromide	12	$5,914
Venlafaxine Hcl	20	$2,485
Dexmethylphenidate Hcl ErDexmethylphenidate Hcl	12	$1,811
Desvenlafaxine Succinate ErDesvenlafaxine Succinate	20	$1,099
Eszopiclone	15	$1,000
Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine	11	$656
Quetiapine Fumarate	29	$607
Lamotrigine	29	$585
Gabapentin	17	$501
Lithium Carbonate	13	$190
Trazodone Hcl	14	$182
Clonazepam	12	$165
Zolpidem Tartrate	17	$130
Topiramate	11	$73
Lorazepam	12	$67

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

Company	Paid to this provider	Part D cost of their drugs
Takeda Pharmaceuticals U.S.A., Inc.Trintellix	$1,408	$5,91412 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,954 psychiatry providers in California.

Other psychiatry in Stanford

Alan SchatzbergStanford$219K
Maurice OhayonStanford$113K
Gustavo AlvaOrange$5.8M
John KooSan Francisco$3M
Jason KelloggIrvine$2.7M
Jonathan MeyerSan Diego$2.3M
Charles Tuan-Tu NguyenIrvine$2.1M
Manoj WaikarLos Gatos$1.9M
Gerald MaguireSan Juan Capistraco$1.8M
Salima BrillmanSunnyvale$1.4M

See the full list for California →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →